Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren

Cjc2.5

CJC-1295 – Forschung

Überwiegend Mechanismus / Beobachtung

9 begutachtete Studien

Was die Evidenz sagt

Überwiegend Mechanismus / Beobachtung

Die meisten Studien zu CJC-1295 sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.

Die meiste Evidenz stammt aus gemischt-qualitativen randomisierten Studien, veröffentlicht 2005–2026 mit einer typischen Studiengröße von 11 Teilnehmenden.

Basierend auf 9 Studien · 1 RCT · 11 Teilnehmende insgesamt

Konfidenz

Geringe Konfidenz

Nach Outcome

GH / IGF-1 axis
Überwiegend Mechanismus / Beobachtung7 Studien
Lean body mass & muscle growthErhöht GH und IGF-1 als Surrogat-Biomarker in humanen PK-Studien, jedoch ohne nachgewiesenen Nutzen für die Körperzusammensetzung oder klinische Endpunkte; eine anhaltende nicht-physiologische GH-Erhöhung stellt einen Kompromiss dar. · Nicht etabliert (keine Endpunktdaten)
Überwiegend Mechanismus / Beobachtung3 Studien
Safety profile
Zu wenige bewertete Studien2 Studien

Stetige Forschung

2 Studien in den letzten 5 Jahren

200520152026

1Systematische Übersicht2026

Finally, we propose a clinically oriented assessment algorithm to support exposure history taking, triage of symptom domains, and risk communication without legitimising off-label peptide regimens.

Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, RuchaŁa M. · Frontiers in endocrinology (2026)

We summarise structural characteristics, pharmacologic effects, and commonly reported dosing patterns, and we synthesise clinically relevant adverse effects with particular attention to hormonal imbalance, endocrine-metabolic risk, and biologically plausible but unproven mitogenic concerns.
Finally, we propose a clinically oriented assessment algorithm to support exposure history taking, triage of symptom domains, and risk communication without legitimising off-label peptide regimens.
Further research warranted to confirm findings

Quelle ansehen

2RCT2006

Subcutaneous administration of CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated, particularly at doses of 30 or 60 microg/kg.

Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. · J Clin Endocrinol Metab (2006)

Two randomized, placebo-controlled, double-blind ascending-dose phase-1 trials in healthy adults aged 21-61 (28- and 49-day durations)
Single subcutaneous dose raised mean plasma GH 2- to 10-fold for ≥6 days and IGF-I 1.5- to 3-fold for 9-11 days; estimated half-life 5.8-8.1 days
After multiple doses, mean IGF-I stayed above baseline for up to 28 days, with evidence of a cumulative effect

Quelle ansehen

3Pilotstudie2006

CJC-1295 increased trough and mean GH secretion and IGF-I production with preserved GH pulsatility.

Ionescu M, Frohman LA. · J Clin Endocrinol Metab (2006)

Healthy men aged 20-40 had overnight GH pulsatility sampled before and 1 week after a single 60 or 90 microg/kg subcutaneous CJC-1295 injection
GH pulse frequency and magnitude were unchanged, but basal (trough) GH rose markedly (7.5-fold), raising mean GH (~46%) and IGF-I (~45%)
No significant difference between the two doses; IGF-I increases did not correlate with GH-secretion parameters

Quelle ansehen

4Tierstudie2005

These results led to the identification of CJC-1295 as a stable and active hGRF(1-29) analog with an extended plasma half-life.

Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. · Endocrinology (2005)

Three maleimido hGRF(1-29) derivatives were bioconjugated to human serum albumin and tested in vitro and in rats
All conjugates resisted dipeptidyl-peptidase-IV and stimulated GH secretion in cultured rat anterior-pituitary cells
CJC-1295 was the best compound (4-fold higher GH AUC vs hGRF(1-29)) and remained detectable in rat plasma beyond 72 h, bound to albumin

Quelle ansehen

5Tierstudie2006

Treatment with once-daily administration of CJC-1295 is able to maintain normal body composition and growth in GHRHKO mice.

Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. · Am J Physiol Endocrinol Metab (2006)

GHRH-knockout mice were treated for 5 weeks with CJC-1295 every 24, 48 or 72 hours
Once-daily dosing normalized body weight and length; every-48/72-h dosing improved but did not fully normalize growth
Relative lean and subcutaneous fat mass were normal in all treated groups

Quelle ansehen

6Tierstudie2009

Treatment of Br-M3-KO mice with CJC-1295, a synthetic GH-releasing hormone (GHRH) analog, rescued the growth deficit displayed by Br-M3-KO mice by restoring normal pituitary size and normal serum GH and IGF-1 levels.

Gautam D, Jeon J, Starost MF, Han SJ, Hamdan FF, Cui Y, Parlow AF, Gavrilova O, Szalayova I, Mezey E, Wess J. · Proc Natl Acad Sci U S A (2009)

Brain-specific M3-muscarinic-receptor knockout mice showed dwarfism with anterior-pituitary hypoplasia and low GH/prolactin
CJC-1295 treatment restored normal pituitary size and normal serum GH and IGF-1, rescuing the growth deficit
Used CJC-1295 as a pharmacological GHRH-axis probe to dissect somatotroph regulation

Quelle ansehen

7Übersicht2026

CJC-1295 combined with ipamorelin showed significantly improved maximum tetanic tension in murine models with glucocorticoid-induced muscle loss, but these findings are limited to animal studies.

Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF, Gamradt SC, Weber AE. · Am J Sports Med (2026)

Independent narrative review of popular injectable peptides (BPC-157, TB-4/TB-500, CJC-1295 + ipamorelin, tesamorelin, GHK-Cu) for orthopaedic/sports use
The only CJC-1295 efficacy signal cited is improved tetanic tension in a murine glucocorticoid-induced muscle-loss model — animal only
Stresses indications, dosing, frequency and duration remain unknown and that safety/efficacy research is needed before recommendations

Quelle ansehen

8Pilotstudien=11 · very small study2009

Serum GH and IGF-1 levels have been shown to increase with administration of GHRH or CJC-1295, a long-acting GHRH analog.

Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. · Growth Horm IGF Res (2009)

Sera from 11 healthy young adult men before and one week after a single CJC-1295 injection were compared by 2-D gel electrophoresis and mass spectrometry
Identified candidate GH/IGF-1 biomarkers: decreased apolipoprotein A1 and transthyretin isoforms; increased beta-hemoglobin and albumin/immunoglobulin fragments
A linear relationship was seen between one immunoglobulin/albumin-fragment spot and IGF-1 levels

Quelle ansehen

9Übersicht2010

CJC-1295 is a releasing factor for growth hormone and is therefore considered a Prohibited Substance under Section S2 of the WADA Prohibited List.

Henninge J, Pepaj M, Hullstein I, Hemmersbach P. · Drug Test Anal (2010)

Norwegian doping laboratory analyzed an unknown illicit pharmaceutical preparation by LC-HRMS/MS
Identified a 29-amino-acid C-terminally amidated peptide whose sequence is consistent with the marketed peptide CJC-1295
States CJC-1295 is a WADA-prohibited substance (Section S2) with potential performance-enhancing effects

Quelle ansehen

In der Forschungsbibliothek ansehen

CJC-1295 – Forschung

Überwiegend Mechanismus / Beobachtung

The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.

Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.

Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.

Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.

Neuronal M3 muscarinic acetylcholine receptors are essential for somatotroph proliferation and normal somatic growth.

Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.

Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation.